| Application number | Title of the application | Filing Date | Status |
|---|
| 09/720215 | Modularly constructed rna molecules having two sequence region types | May 1, 2001 | Abandoned |
Array
(
[id] => 6258636
[patent_doc_number] => 20020187132
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2002-12-12
[patent_title] => 'Cardiac gene transfer'
[patent_app_type] => new
[patent_app_number] => 09/846034
[patent_app_country] => US
[patent_app_date] => 2001-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 8679
[patent_no_of_claims] => 51
[patent_no_of_ind_claims] => 18
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0187/20020187132.pdf
[firstpage_image] =>[orig_patent_app_number] => 09846034
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/846034 | Cardiac gene transfer | Apr 29, 2001 | Abandoned |
Array
(
[id] => 6066577
[patent_doc_number] => 20020032912
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2002-03-14
[patent_title] => 'Method of identifying agents that alter the activity of the promoter sequence for corticotropin releasing-factor receptor CRF2a'
[patent_app_type] => new
[patent_app_number] => 09/847852
[patent_app_country] => US
[patent_app_date] => 2001-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 4502
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0032/20020032912.pdf
[firstpage_image] =>[orig_patent_app_number] => 09847852
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/847852 | Method of identifying agents that alter the activity of the promoter sequence for corticotropin releasing-factor receptor CRF2a | Apr 29, 2001 | Abandoned |
Array
(
[id] => 6797102
[patent_doc_number] => 20030175976
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-09-18
[patent_title] => 'Clean synthetic vectors, plasmids, transgenic plants and plant parts containing them, and methods for obtaining them'
[patent_app_type] => new
[patent_app_number] => 09/845064
[patent_app_country] => US
[patent_app_date] => 2001-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 22515
[patent_no_of_claims] => 54
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0175/20030175976.pdf
[firstpage_image] =>[orig_patent_app_number] => 09845064
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/845064 | Clean synthetic vectors, plasmids, transgenic plants and plant parts containing them, and methods for obtaining them | Apr 26, 2001 | Abandoned |
| 09/830703 | Transgenic animal model for neurodegenerative diseases | Apr 25, 2001 | Abandoned |
Array
(
[id] => 1392281
[patent_doc_number] => 06541251
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2003-04-01
[patent_title] => 'Pancreatic progenitor 1 gene and its uses'
[patent_app_type] => B1
[patent_app_number] => 09/844497
[patent_app_country] => US
[patent_app_date] => 2001-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12457
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/541/06541251.pdf
[firstpage_image] =>[orig_patent_app_number] => 09844497
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/844497 | Pancreatic progenitor 1 gene and its uses | Apr 25, 2001 | Issued |
Array
(
[id] => 7414196
[patent_doc_number] => 20040025197
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-02-05
[patent_title] => 'Transgenic animal'
[patent_app_type] => new
[patent_app_number] => 10/258561
[patent_app_country] => US
[patent_app_date] => 2002-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 15560
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0025/20040025197.pdf
[firstpage_image] =>[orig_patent_app_number] => 10258561
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/258561 | Transgenic animal | Apr 23, 2001 | Issued |
Array
(
[id] => 7095265
[patent_doc_number] => 20010034885
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2001-10-25
[patent_title] => 'Non-human animal deficient in function of pituitary adenylate cyclase-activating polypeptide gene'
[patent_app_type] => new
[patent_app_number] => 09/835627
[patent_app_country] => US
[patent_app_date] => 2001-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 2819
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0034/20010034885.pdf
[firstpage_image] =>[orig_patent_app_number] => 09835627
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/835627 | Non-human animal deficient in function of pituitary adenylate cyclase-activating polypeptide gene | Apr 16, 2001 | Abandoned |
Array
(
[id] => 5859846
[patent_doc_number] => 20020123473
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2002-09-05
[patent_title] => 'IL-12 gene expression and delivery systems and uses'
[patent_app_type] => new
[patent_app_number] => 09/836866
[patent_app_country] => US
[patent_app_date] => 2001-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 15579
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0123/20020123473.pdf
[firstpage_image] =>[orig_patent_app_number] => 09836866
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/836866 | IL-12 gene expression and delivery systems and uses | Apr 15, 2001 | Abandoned |
| 09/743097 | Cartilage cell differentiation promoters | Apr 9, 2001 | Abandoned |
Array
(
[id] => 6947892
[patent_doc_number] => 20010021526
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2001-09-13
[patent_title] => 'Cellular and animal models for diseases associated with mitochondrial defects'
[patent_app_type] => new
[patent_app_number] => 09/825525
[patent_app_country] => US
[patent_app_date] => 2001-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 9856
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 9
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0021/20010021526.pdf
[firstpage_image] =>[orig_patent_app_number] => 09825525
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/825525 | Cellular and animal models for diseases associated with mitochondrial defects | Apr 1, 2001 | Abandoned |
| 09/818647 | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | Mar 27, 2001 | Abandoned |
Array
(
[id] => 1395602
[patent_doc_number] => 06534062
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2003-03-18
[patent_title] => 'Methods for increasing a cytotoxic T lymphocyte response in vivo'
[patent_app_type] => B2
[patent_app_number] => 09/820484
[patent_app_country] => US
[patent_app_date] => 2001-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 38
[patent_no_of_words] => 23412
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/534/06534062.pdf
[firstpage_image] =>[orig_patent_app_number] => 09820484
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/820484 | Methods for increasing a cytotoxic T lymphocyte response in vivo | Mar 27, 2001 | Issued |
Array
(
[id] => 5985879
[patent_doc_number] => 20020098540
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2002-07-25
[patent_title] => 'Novel polypeptides, and nucleic acids encoding the same'
[patent_app_type] => new
[patent_app_number] => 09/815248
[patent_app_country] => US
[patent_app_date] => 2001-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 30002
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0098/20020098540.pdf
[firstpage_image] =>[orig_patent_app_number] => 09815248
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/815248 | Novel polypeptides, and nucleic acids encoding the same | Mar 21, 2001 | Abandoned |
Array
(
[id] => 1175186
[patent_doc_number] => 06743423
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2004-06-01
[patent_title] => 'Use of adeno-associated viruses for decreasing the radiotherapy-induced or chemotherapy- induced resistance in cancer patients'
[patent_app_type] => B1
[patent_app_number] => 09/719336
[patent_app_country] => US
[patent_app_date] => 2001-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 3376
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/743/06743423.pdf
[firstpage_image] =>[orig_patent_app_number] => 09719336
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/719336 | Use of adeno-associated viruses for decreasing the radiotherapy-induced or chemotherapy- induced resistance in cancer patients | Mar 21, 2001 | Issued |
Array
(
[id] => 6635377
[patent_doc_number] => 20030211612
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-11-13
[patent_title] => 'Establishment of cellular manipulations which enhance oligo-mediated gene targeting'
[patent_app_type] => new
[patent_app_number] => 10/239595
[patent_app_country] => US
[patent_app_date] => 2003-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 22193
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0211/20030211612.pdf
[firstpage_image] =>[orig_patent_app_number] => 10239595
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/239595 | Establishment of cellular manipulations which enhance oligo-mediated gene targeting | Mar 21, 2001 | Issued |
Array
(
[id] => 1182282
[patent_doc_number] => 06737559
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2004-05-18
[patent_title] => 'See-through medaka'
[patent_app_type] => B2
[patent_app_number] => 09/814047
[patent_app_country] => US
[patent_app_date] => 2001-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 0
[patent_no_of_words] => 10418
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/737/06737559.pdf
[firstpage_image] =>[orig_patent_app_number] => 09814047
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/814047 | See-through medaka | Mar 21, 2001 | Issued |
Array
(
[id] => 6473395
[patent_doc_number] => 20020022255
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2002-02-21
[patent_title] => 'Transgenic mice containing sulfotransferase gene disruptions'
[patent_app_type] => new
[patent_app_number] => 09/816790
[patent_app_country] => US
[patent_app_date] => 2001-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 24692
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 14
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0022/20020022255.pdf
[firstpage_image] =>[orig_patent_app_number] => 09816790
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/816790 | Transgenic mice containing sulfotransferase gene disruptions | Mar 21, 2001 | Abandoned |
Array
(
[id] => 6414454
[patent_doc_number] => 20020038467
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2002-03-28
[patent_title] => 'Transgenic mice containing melanocyte stimulating hormone receptor gene disruptions'
[patent_app_type] => new
[patent_app_number] => 09/815944
[patent_app_country] => US
[patent_app_date] => 2001-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 24487
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 14
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0038/20020038467.pdf
[firstpage_image] =>[orig_patent_app_number] => 09815944
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/815944 | Transgenic mice containing melanocyte stimulating hormone receptor gene disruptions | Mar 21, 2001 | Abandoned |
Array
(
[id] => 6649785
[patent_doc_number] => 20020088012
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2002-07-04
[patent_title] => 'Transgenic mice containing lymphoid-specific GPCR gene disruptions'
[patent_app_type] => new
[patent_app_number] => 09/815937
[patent_app_country] => US
[patent_app_date] => 2001-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 25670
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 17
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0088/20020088012.pdf
[firstpage_image] =>[orig_patent_app_number] => 09815937
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/815937 | Transgenic mice containing lymphoid-specific GPCR gene disruptions | Mar 21, 2001 | Abandoned |
